Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions

Merkel Cell Carcinoma

Interventions

DRUG

Pembrolizumab

400mg IV

Trial Locations (1)

RECRUITING

Penn Medicine, Philadelphia

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER